Guidelines for the use of platinib and analysis of its potential side effects.

Platinib, as a targeted drug targeting RET mutations, is mainly used to treat adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer who have previously received platinum-based chemotherapy. In addition, it has also shown therapeutic efficacy in cancers such asRETmutated medullary thyroid carcinoma.

The recommended dose is 400 mg daily until disease progression or intolerable toxicity occurs. It should be taken at the same time every day, and should be taken orally on an empty stomach, that is, avoid eating for at least 1-2 hours before and after taking the medicine.

During treatment, patients should receive regular examinations and evaluations from their doctors to ensure the effectiveness and safety of the medication. If adverse reactions occur, the doctor may adjust the dose based on the patient's tolerance.

1.Common side effects: including constipation, high blood pressure, fatigue, musculoskeletal pain and diarrhea. These side effects are mostly mild to moderate and can usually be alleviated with appropriate medication adjustments or supportive care.

2.Specific adverse reactions: such as interstitial lung disease/non-infectious pneumonia, liver toxicity, bleeding events, etc. These reactions can be serious and patients need to be monitored closely and report any unusual symptoms to their doctor promptly.

In patients with uncontrolled hypertension, baseline measurements should be obtained before initiating treatment and blood pressure should be monitored routinely during treatment. In addition, pregnant women and people who are allergic to the ingredients of the drug should avoid using Platinib.

Platinib, as a highly effective targeted therapy, provides a new treatment option for cancer patients with RET mutations. However, it should be used with caution, following clear application guidelines, and paying close attention to possible side effects.